



Improving the interoperability and reusability of CRUK-funded research data: key considerations for adopting the OMOP Common Data Model

The opportunity: Cancer Research UK (CRUK) funds ~£400 million of research per year, with each project using or generating valuable cancer data. However, the collective impact of this research could be amplified by standardising the data produced, e.g., by using a common data model (CDM), facilitating its integration and re-use in a wide range of future projects.



CDM, Common Data Model; CRUK, Cancer Research UK; OMOP, Observational Medical Outcomes Partnership

We conducted a SWOT analysis to identify factors that may enable or hinder OMOP-CDM adoption



SWOT, Strengths, Weaknesses, Opportunities, Threats

SWOT, Strengths, Weaknesses, Opportunities, Threats


We included the perspectives of people across the cancer data pipeline

Table 1. Participant Characteristics	All N (%)	Survey N (%)	Mixed Focus Group N (%)	Patient Focus Group N (%)
Total	38 (100)	18 (100)	10 (100)	10 (100)
Role				
Researcher	7 (18.4)	6 (33.3)	1 (10)	0 (0)
Healthcare professional	4 (10.5)	0 (0)	4 (40)	0 (0)
Patient or patient advocate	11 (28.9)	1 (5.6)	0 (0)	10 (100)
Technical data-focussed role*	8 (21.1)	6 (33.3)	2 (20)	0 (0)
Other supportive role†	8 (21.1)	5 (27.8)	3 (30)	0 (0)

* Such as data analyst, data scientist, database manager, data engineer, IT services.
† Such as project management, governance, partnerships

OMOP, Observational Medical Outcomes Partnership

We documented the salient themes across each of the four SWOT domains



The impact: The identified SWOT themes will be used to inform the development of a strategy for OMOP-CDM adoption across CRUK-funded research, alongside learnings from a wider programme of work which includes a technical pilot study to standardise pre-existing CRUK-funded cancer research datasets.